FAQ

GL-ONC1

Known as: GLV-1h68 
 

Topic mentions per year

Topic mentions per year

2007-2017
024620072017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus
Oncolytic viruses show promise for treating cancer. However, to assess therapeutic efficacy and potential toxicity, a noninvasive… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
GLV-1h68 is an attenuated recombinant vaccinia virus (VACV) that selectively colonizes established human xenografts inducing… (More)
Is this relevant?
2009
2009
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68.
Oncolytic virotherapy of tumors has shown promising results in both preclinical and clinical studies. Here, we investigated the… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2009
2009
The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation
As a new anticancer treatment option, vaccinia virus (VACV) has shown remarkable antitumor activities (oncolysis) in preclinical… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2009
2009
Oncolytic vaccinia therapy of squamous cell carcinoma
Novel therapies are necessary to improve outcomes for patients with squamous cell carcinomas (SCC) of the head and neck… (More)
Is this relevant?
2009
2009
A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging.
Noninvasive and repetitive monitoring of a virus in target tissues and/or specific organs of the body is highly desirable for the… (More)
Is this relevant?
2008
2008
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
Malignant pleural mesothelioma (MPM) is a fatal disease with a median survival of less than 14 months. For the first time, a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo.
CONTEXT Anaplastic thyroid carcinoma (ATC) is a fatal disease with a median survival of only 6 months. Novel therapies are needed… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.
Previously, we reported that a recombinant vaccinia virus (VACV) carrying a light-emitting fusion gene enters, replicates in, and… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2007
2007
Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus.
BACKGROUND Anaplastic thyroid carcinoma (ATC) is a fatal disease resistant to all conventional treatments. Novel therapies are… (More)
Is this relevant?